Clinical Trial Update: Study Of Ruxolitinib (INCB018424) With Preoperative Chemotherapy For Triple Negative Inflammatory Breast Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating ruxolitinib in combination with preoperative chemotherapy for triple-negative inflammatory breast cancer; the study is not recruiting a…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Inflammatory Breast Cancer

Drugs mentioned

• Ruxolitinib (ruxolitinib)

Snippet

Sponsor: Dana-Farber Cancer Institute | Conditions: Inflammatory Breast Cancer (IBC) | Phase 2 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2024-04-18